|
|
|
|
| LEADER |
00000cam a2200000 a 4500 |
| 001 |
2590606 |
| 003 |
ICU |
| 005 |
20030523063700.0 |
| 008 |
970304s1996 maua b 001 0 eng c |
| 010 |
|
|
|a 96041439
|
| 020 |
|
|
|a 0792342577 (acid
|
| 035 |
|
|
|a (ICU)BID22904421
|
| 035 |
|
|
|a (NhCcYBP)YBP
|
| 040 |
|
|
|a DNLM/DLC
|c DLC
|d DLC
|d OrLoB-B
|d OCoLC
|
| 041 |
0 |
|
|a eng
|
| 050 |
0 |
0 |
|a R853.C55
|b B85 1996
|
| 060 |
|
0 |
|a W 20.5.B939r 1996
|
| 082 |
0 |
0 |
|a 615.5/0724
|2 20
|
| 100 |
1 |
|
|a Bulpitt, Christopher J.
|0 http://id.loc.gov/authorities/names/n82131079
|1 http://viaf.org/viaf/66638085
|
| 245 |
1 |
0 |
|a Randomised controlled clinical trials /
|c Christopher J. Bulpitt.
|
| 250 |
|
|
|a 2nd ed.
|
| 260 |
|
|
|a Boston :
|b Kluwer Academic Publishers,
|c c1996.
|
| 300 |
|
|
|a ix, 437 p. :
|b ill. ;
|c 24 cm.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|0 http://id.loc.gov/vocabulary/contentTypes/txt
|
| 337 |
|
|
|a unmediated
|b n
|2 rdamedia
|0 http://id.loc.gov/vocabulary/mediaTypes/n
|
| 338 |
|
|
|a volume
|b nc
|2 rdacarrier
|0 http://id.loc.gov/vocabulary/carriers/nc
|
| 504 |
|
|
|a Includes bibliographical references (p. 387-426) and index.
|
| 505 |
0 |
0 |
|g 1.
|t Introduction --
|g 2.
|t The history of controlled trials --
|g 3.
|t Ethical considerations --
|g 4.
|t The objectives of a randomised controlled trial --
|g 5.
|t Different trial designs --
|g 6.
|t How many subjects are required for a trial? --
|g 7.
|t How to ensure that the results are free of bias --
|g 8.
|t Writing the protocol --
|g 9.
|t Recruitment of subjects --
|g 10.
|t Information to be collected during a trial --
|g 11.
|t The conduct of the trial - Good Clinical Practice --
|g 12.
|t Stopping rules for trials --
|g 13.
|t The variability and validity of results --
|g 14.
|t Analysis of the results, subgroup and meta-analysis --
|g 15.
|t The evaluation of subjective well-being and measurement of quality of life --
|g 16.
|t The detection of adverse drug reactions --
|g 17.
|t Measurement of the benefit: risk comparison, cost-effectiveness and cost-utility --
|g 18.
|t Early trials on new drugs --
|g 19.
|t Failure to accept the results of randomised controlled trials --
|g 20.
|t The advantages and disadvantages of randomised controlled trials.
|
| 650 |
|
0 |
|a Clinical trials.
|0 http://id.loc.gov/authorities/subjects/sh85027069
|
| 650 |
1 |
2 |
|a Clinical Trials as Topic.
|
| 650 |
2 |
2 |
|a Randomised Controlled Trials.
|
| 650 |
|
7 |
|a Clinical trials.
|2 fast
|0 http://id.worldcat.org/fast/fst00864429
|
| 901 |
|
|
|a ToCBNA
|
| 903 |
|
|
|a HeVa
|
| 035 |
|
|
|a (OCoLC)35360729
|
| 929 |
|
|
|a cat
|
| 999 |
f |
f |
|i e11cc83b-d83a-523f-9aa3-b83195f555bf
|s 302bab5f-110d-5b3f-b2c3-87f6e2895ba4
|
| 928 |
|
|
|t Library of Congress classification
|a R853.C55B85 1996
|l ASR
|c ASR-SciASR
|i 3266264
|
| 927 |
|
|
|t Library of Congress classification
|a R853.C55B85 1996
|l ASR
|c ASR-SciASR
|e mayb
|e CRERAR
|b 44780625
|i 4775646
|
